{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 75 of 122', 'For subjects with asthma, the evaluation of asthma severity will be assessed using the', 'classification in Table 19.', 'Asthma control in subjects with pre-existing asthma will be assessed using scores from the', 'Asthma Control Test (ACT) (Schatz, 2006) and by the incidence of asthma rescue', 'medication use. The ACT is a self-administered, 5-item questionnaire for subjects aged', '> 12 years, used to evaluate the level of asthma control in the last 4 weeks. Each question is', 'presented on a 5-point scale, with lower numbers indicating worse asthma control.', 'A composite score of more than 19 indicates well-controlled asthma.', 'The Childhood Asthma Control Test (C-ACT) is a 7-item questionnaire used to evaluate the', 'level of asthma control in subjects aged 4 to 11 years with pre-existing asthma (Liu, 2007).', 'Subjects complete the first part of the questionnaire, which consists of 4 questions and a', 'choice of 4 responses from 0 (worse asthma) to 3 (controlled asthma) for each question. The', 'parent/caregiver may help the subject read or understand the question if needed, but only the', 'subject should select the response. The parent/caregiver completes the second part of the', 'questionnaire, which consists of 3 questions and a choice of 6 responses from 0 (worse', 'asthma) to 5 (controlled asthma) for each question. Parents/caregivers are asked to recall', 'asthma symptoms in the last 4 weeks and complete their portion of the questionnaire without', \"influence from the subject's responses. A composite score of more than 19 indicates\", 'well-controlled asthma.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 76 of 122', 'Table 19: Evaluation of Asthma Based on NHLBI Criteria', 'Intermittent', 'Persistent: Mild', 'Persistent: Moderate', 'Persistent: Severe', 'Classification', '(Step 1)', '(Step 2)', '(Step 3 or 4)', '(Step 5 or 6)', 'Symptoms', '<2 days/week', '> 2 days/week but not daily', 'Daily', 'Throughout the day', 'Night-time awakenings', 'Subject aged 0-4 years', '0', '1-2 times/month', '3-4 times/month', '> 1 time/week', 'Subject aged > 5 years', '<: 2 times/month', '3-4 times/month', '> 1 time/week but not nightly', 'Often 7 times/week', 'Short-acting inhaled', '<2 days/week', '> 2 days/week, but not daily', 'Daily', 'Several times per day', 'beta2-agonist use', '(and not more than once a day', 'for subject 12 years)', 'Interference with normal', 'None', 'Minor limitation', 'Some limitation', 'Extremely limited', 'activity', 'Lung function', 'Subject aged 0-4 years', 'Not applicable', 'Not applicable', 'Not applicable', 'Not applicable', 'Subject aged 5-11 years', 'Normal FEV1 between', 'FEV1 80% predicted', 'FEV1 > 60% but < 80%', 'FEV1 < 60% predicted', 'exacerbations', 'FEV1/FVC > 80% and VI 85%', 'predicted', 'FEV1/FVC < 75%', 'FEV1 > 80% predicted', 'FEV1/FVC > 75% and VI 80%', 'FEV1/FVC > 85%', 'Subject aged > 12 years', 'Normal FEV1 between', 'FEV1 > 80% predicted', 'FEV1 > 60% but < 80%', 'FEV1 < 60% predicted', 'exacerbations', 'FEV1/FVC normal [1]', 'predicted', 'FEV1/FVC reduced > 5% [1]', 'FEV1 > 80% predicted', 'FEV1/FVC reduced VI 5% [1]', 'FEV1/FVC normal [1]', 'Adapted from NHLBI, 2007.', '[1] Normal FEV1/FVC by age: 8-19 years, 85%; 20-39 years, 80%; 40-59 years, 75%; 60-80 years, 70%.', 'FEV1, forced expiratory volume in the first second of expiration; FVC, forced vital capacity.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 77 of 122', '9.3.2', 'TNSS Questionnaires', 'The Total Nasal Symptom Score (TNSS) is used to assess the severity of allergic rhinitis and', 'will be administered only to subjects with pre-existing allergic rhinitis. The TNSS (short', 'form) consists of 3 questions that address nasal obstruction, rhinorrhea, and nasal', 'itch/sneezing (Downie, 2004). Each question has a choice of 4 responses that range from', '0 (no symptoms) to 3 (severe symptoms). The subject is asked to recall symptoms over the', 'last week to allow calculation of the symptom score.', '9.3.3', 'SCORAD Index', 'The scoring atopic dermatitis (SCORAD) index is used to assess the severity of atopic', 'dermatitis and will be administered only to subjects with pre-existing atopic dermatitis', '(European Task Force on Atopic Dermatitis, 1993). The SCORAD index is based on the', 'combination of the following:', 'Extent of lesions (accounts for about 20% of the total score).', 'Intensity, based on 6 items (erythema, edema/papulation, oozing/crusts, excoriations,', 'lichenification, and dryness), each graded from 0 (absent) to 3 (severe) according to', 'reference photographs (accounts for about 60% of the total score).', 'Subjective items (pruritus and sleep loss). The subject (aged >7 years) or', 'parent/caregiver will indicate the average value for pruritus and sleep loss on a visual', 'analog scale (accounts for about 20% of the total score).', '9.3.4', 'PEESS v2.0 Questionnaire', 'The PEESS v2.0 (Martin, 2015; Franciosi, 2011) is used to assess the frequency and severity', 'of EoE symptoms in the last month and will be administered only for subjects with GI', 'adverse events of interest (Section 5.5.1, Section 8.5.6.2). The PEESS v2.0 consists of', '4 domains (dysphagia, GERD, nausea/vomiting, and pain) and 20 items. Each item contains', 'response options from 0 to 4. A higher total or domain score indicates more frequent and/or', 'severe symptoms. The parent/caregiver completes the Parent Report and subjects aged', '> 8 years complete the Children and Teens Report.', 'The PEESS v2.0 was not designed to establish a diagnosis of EoE; the use of this', 'questionnaire to monitor the clinical course of GI symptoms must be considered exploratory.', 'However, the PEESS v2.0 has shown content and construct validity (Martin, 2015;', 'Franciosi, 2011) and is a promising tool for following the clinical course of EoE or an', 'EoE-like immune-mediated GI syndrome. The questionnaire has the potential to reveal', 'trends toward symptomatic improvement or worsening that may otherwise go undetected.', '9.3.5', 'Physical Examinations and Vital Signs', 'The investigator will perform physical examinations according to the schedule of activities.']\n\n###\n\n", "completion": "END"}